Cellular immunotherapy for high grade gliomas: mathematical analysis deriving efficacious infusion rates based on patient requirements
From MaRDI portal
Publication:3068620
Recommendations
- The impact of immunotherapy on a glioma immune interaction model
- Quantifying the role of immunotherapeutic drug T11 target structure in progression of malignant gliomas: mathematical modeling and dynamical perspective
- Stability analysis of a mathematical model for glioma-immune interaction under optimal therapy
- A strategy of optimal efficacy of T11 target structure in the treatment of brain tumor
- Tumor control, elimination, and escape through a compartmental model of dendritic cell therapy for melanoma
Cited in
(23)- Modeling CAR T-cell therapy with patient preconditioning
- CAR T cells for T-cell leukemias: insights from mathematical models
- Thresholds for extinction and proliferation in a stochastic tumour-immune model with pulsed comprehensive therapy
- The impact of immunotherapy on a glioma immune interaction model
- On a discrete model of tumour-immune system interactions with blockade of immune checkpoints
- A mathematical model for a T cell fate decision algorithm during immune response
- Additional extension of the mathematical model for BCG immunotherapy of bladder cancer and its validation by auxiliary tool
- Global stability and parameter analysis reinforce therapeutic targets of PD-L1-PD-1 and MDSCs for glioblastoma
- Logistic tumor growth with delay and impulsive treatment
- An immune system-tumour interactions model with discrete time delay: model analysis and validation
- Quantifying the role of immunotherapeutic drug T11 target structure in progression of malignant gliomas: mathematical modeling and dynamical perspective
- Asymptotic dynamics of some t-periodic one-dimensional model with application to prostate cancer immunotherapy
- On the analysis of a mathematical model of CAR-T cell therapy for glioblastoma: insights from a mathematical model
- Study of dose-dependent combination immunotherapy using engineered T cells and IL-2 in cervical cancer
- Dynamics of tumor-\( \text{CD}4^+\)-cytokine-host cells interactions with treatments
- About a generalized model of lymphoma
- Optimal control for a mathematical model of glioma treatment with oncolytic therapy and TNF-\(\alpha \) inhibitors
- Tractable model of malignant gliomas immunotherapy with discrete time delays
- A mathematical model of the enhancement of tumor vaccine efficacy by immunotherapy
- Analysis of the Hopf bifurcation for the family of angiogenesis models. II: The case of two nonzero unequal delays
- Modelling pulsed immunotherapy of tumour-immune interaction
- Modelling effects of a chemotherapeutic dose response on a stochastic tumour-immune model
- A structural methodology for modeling immune-tumor interactions including pro- and anti-tumor factors for clinical applications
This page was built for publication: Cellular immunotherapy for high grade gliomas: mathematical analysis deriving efficacious infusion rates based on patient requirements
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q3068620)
